A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity

Simply Wall St.04-19

Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628767667?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-19 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628767667","market":"nz","top_or_hot":-1,"title":"A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity","media":"Simply Wall St.","content":"<div>\n<p>Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-19 20:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2","article_id":"2628767667","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/a-look-at-neurocrine-biosciences-nbix-valuation-after-new-in-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628767667","pubTimestamp":1776600418,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity implying expectations for larger share moves.\nSee our latest analysis for Neurocrine Biosciences.\nThe INGREZZA persistence data and recent M&A call interest come as the share price sits at US$133.25, with a 1 month share price return of 4.36% but a year to date share price decline of 5.23%, while...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","NBIX":"神经分泌生物科学"},"translate_title":"新INGREZZA持久性数据和期权活动后Neurocrine Biosciences(NBIX)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1.5},"content_text":"Neurocrine Biosciences (NBIX) is back in focus after new real world data showed higher treatment persistence for INGREZZA versus AUSTEDO XR in tardive dyskinesia, alongside elevated options activity implying expectations for larger share moves. See our latest analysis for Neurocrine Biosciences. The INGREZZA persistence data and recent M&A call interest come as the share price sits at US$133.25, with a 1 month share price return of 4.36% but a year to date share price decline of 5.23%, while the 1 year total shareholder return of 31.44% points to momentum that has been building over a longer horizon. If this kind of real world clinical traction has your attention, it can be worth seeing what else is moving in healthcare focused AI by checking out 36 healthcare AI stocks With INGREZZA’s real world persistence data in hand, a share price of US$133.25 and a sizeable gap to published analyst targets, the key question is whether Neurocrine is still underappreciated or if the market already reflects its future potential. AdvertisementMost Popular Narrative: 25.2% Undervalued At US$133.25, the most widely followed narrative pegs Neurocrine Biosciences' fair value at US$178.04, implying a sizeable gap that hinges on execution in its key franchises and late stage pipeline.  A broad, late stage and diversified CNS pipeline including multiple Phase III programs targeting major depressive disorder and schizophrenia leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.  Read the complete narrative. Want to see what is baked into that fair value gap? The story leans heavily on compounding revenue, rising margins, and a richer earnings multiple tied to those outcomes. Result: Fair Value of $178.04 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that gap relies heavily on INGREZZA and CRENESSITY, so tougher payer terms or slower than expected uptake in key programs could quickly pressure the story. Find out about the key risks to this Neurocrine Biosciences narrative. Another View: Valuation Looks Full On Earnings The DCF work presents Neurocrine Biosciences as heavily undervalued, yet the current P/E of 27.9x tells a different story. That is richer than the US Biotechs industry at 17.1x, peers at 21.5x, and the fair ratio of 21.6x, which could mean less margin for error if expectations soften. Where do you think the market adjusts first: the story, or the multiple? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:NBIX P/E Ratio as at Apr 2026Next Steps If this mix of optimism and caution has you thinking carefully about Neurocrine, it makes sense to review the underlying drivers and risks for yourself, starting with the 4 key rewards. Looking for more investment ideas? If Neurocrine has sharpened your thinking, do not stop here. A broader watchlist can help you spot opportunities before they are crowded.  Target long term upside potential by scanning screener containing 23 high quality undiscovered gems that pair solid fundamentals with limited market attention. Strengthen your portfolio core by focusing on companies in the solid balance sheet and fundamentals stocks screener (42 results) that prioritize resilience and financial discipline. Dial down volatility risk by zeroing in on the 71 resilient stocks with low risk scores that score well on stability while still offering room for returns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neurocrine Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628767667","isCrawlerRequest":true}